6.00
price up icon3.63%   0.21
pre-market  Vorhandelsmarkt:  6.29   0.29   +4.83%
loading
Schlusskurs vom Vortag:
$5.79
Offen:
$5.87
24-Stunden-Volumen:
376.72K
Relative Volume:
1.70
Marktkapitalisierung:
$270.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.74M
KGV:
-7.3171
EPS:
-0.82
Netto-Cashflow:
$-24.89M
1W Leistung:
+0.17%
1M Leistung:
-44.65%
6M Leistung:
-49.20%
1J Leistung:
-38.21%
1-Tages-Spanne:
Value
$5.82
$6.38
1-Wochen-Bereich:
Value
$5.5977
$6.38
52-Wochen-Spanne:
Value
$5.5977
$16.94

Third Harmonic Bio Inc Stock (THRD) Company Profile

Name
Firmenname
Third Harmonic Bio Inc
Name
Telefon
(209) 727-2457
Name
Adresse
1700 MONTGOMERY STREET, SAN FRANCISCO
Name
Mitarbeiter
51
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
THRD's Discussions on Twitter

Vergleichen Sie THRD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
THRD
Third Harmonic Bio Inc
6.00 270.35M 0 -32.74M -24.89M -0.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-09 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-06-18 Eingeleitet Stifel Buy
2024-06-07 Eingeleitet Raymond James Outperform
2022-12-16 Herabstufung Jefferies Buy → Hold
2022-12-15 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-10-10 Eingeleitet Cowen Outperform
2022-10-10 Eingeleitet Jefferies Buy
2022-10-10 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Third Harmonic Bio Inc Aktie (THRD) Neueste Nachrichten

pulisher
Jan 18, 2025

Trend Tracker for (THRD) - Stock Traders Daily

Jan 18, 2025
pulisher
Jan 14, 2025

Jefferies cuts Third Harmonic stock target to $7 from $15 By Investing.com - Investing.com Canada

Jan 14, 2025
pulisher
Jan 13, 2025

Third Harmonic Bio shares drop to lowest since 2023 By Investing.com - Investing.com Canada

Jan 13, 2025
pulisher
Jan 10, 2025

Third Harmonic Bio stock hits 52-week low at $8.04 - Investing.com India

Jan 10, 2025
pulisher
Jan 09, 2025

Dermata Therapeutics Inc (DRMA): Major Improvements, Worth A Look - Stocks Register

Jan 09, 2025
pulisher
Jan 08, 2025

Stifel maintains positive outlook on Celldex and Third Harmonic stocks By Investing.com - Investing.com Canada

Jan 08, 2025
pulisher
Jan 08, 2025

Revance gains as it plans to enter talks with Teoxane on likely superior bid (RVNC:NASDAQ) - Seeking Alpha

Jan 08, 2025
pulisher
Jan 07, 2025

Learn to Evaluate (THRD) using the Charts - Stock Traders Daily

Jan 07, 2025
pulisher
Jan 07, 2025

Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews

Jan 07, 2025
pulisher
Jan 06, 2025

Revance Therapeutics jumps after Teoxane offers $3.60 a share (NASDAQ:RVNC) - Seeking Alpha

Jan 06, 2025
pulisher
Jan 03, 2025

Eton acquires Wilson disease drug Galzin (ETON:NASDAQ) - Seeking Alpha

Jan 03, 2025
pulisher
Jan 02, 2025

Neumora stock drops on depression trial failure (NMRA:NASDAQ) - Seeking Alpha

Jan 02, 2025
pulisher
Dec 28, 2024

Trading (THRD) With Integrated Risk Controls - Stock Traders Daily

Dec 28, 2024
pulisher
Dec 19, 2024

Aquestive receives FDA Orphan Drug Exclusivity for Libervant - Seeking Alpha

Dec 19, 2024
pulisher
Dec 17, 2024

Long Term Trading Analysis for (THRD) - Stock Traders Daily

Dec 17, 2024
pulisher
Dec 17, 2024

Third Harmonic Bio's SWOT analysis: oral KIT inhibitor stock shows promise - Investing.com Australia

Dec 17, 2024
pulisher
Dec 10, 2024

Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress - Investing.com India

Dec 10, 2024
pulisher
Dec 10, 2024

Stock Market Analysis & Tools for Investors - Seeking Alpha

Dec 10, 2024
pulisher
Dec 10, 2024

Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress By Investing.com - Investing.com South Africa

Dec 10, 2024
pulisher
Dec 09, 2024

Revance Therapeutics plunges after Crown Labs cuts takeover price in half - Seeking Alpha

Dec 09, 2024
pulisher
Dec 05, 2024

Atlas Venture Announces $450 Million Fund XIV - Yahoo Finance

Dec 05, 2024
pulisher
Nov 26, 2024

How the (THRD) price action is used to our Advantage - Stock Traders Daily

Nov 26, 2024
pulisher
Nov 25, 2024

Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference - Marketscreener.com

Nov 25, 2024
pulisher
Nov 25, 2024

Third Harmonic Bio to Present at Evercore HealthCONx Conference in December | THRD Stock News - StockTitan

Nov 25, 2024
pulisher
Nov 20, 2024

Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Aclaris stock soars for second day on licensing deal, analyst upgrades (NASDAQ:ACRS) - Seeking Alpha

Nov 19, 2024
pulisher
Nov 15, 2024

(THRD) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 15, 2024
pulisher
Nov 15, 2024

RA Capital Management Reduces Stake in Third Harmonic Bio Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Significant Stake Increase by T. Rowe Price in Third Harmonic Bi - GuruFocus.com

Nov 14, 2024
pulisher
Nov 12, 2024

Revance Therapeutics jumps after Crown Laboratories tender offer extended again - Seeking Alpha

Nov 12, 2024
pulisher
Nov 11, 2024

Vertiv Rises 13% in a Month: Time for Investors to Buy the Stock? - MSN

Nov 11, 2024
pulisher
Nov 11, 2024

Shiba Inu (SHIB) Price Rises 53% but Hits Rejection at Key Ascending Resistance Level - MSN

Nov 11, 2024
pulisher
Nov 08, 2024

Canopy Growth stock on watch after Q2 results (CGC:NASDAQ) - Seeking Alpha

Nov 08, 2024
pulisher
Nov 08, 2024

Third Harmonic Bio Reports Q3 2024 Financial Results - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Third Harmonic Bio Inc (THRD) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Third Harmonic Bio (THRD) to Present at Major Stifel, Jefferies Healthcare Conferences | THRD Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Marquis Who's Who Honors Jonathan Colon, PhD, for Expertise in Biotechnology - 24-7 Press Release

Nov 07, 2024
pulisher
Nov 07, 2024

Third Harmonic Flat on Q3 Results - Baystreet.ca

Nov 07, 2024
pulisher
Nov 07, 2024

Third Harmonic Bio Announces Third Quarter 2024 Financial Results - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Third Harmonic Bio Reports $296M Cash Position, Phase 1 Trial Progress Despite Wider Q3 Loss | THRD Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

An RNAi renaissance is creating a new generation of startups - BioPharma Dive

Nov 06, 2024
pulisher
Nov 04, 2024

(THRD) Technical Data - Stock Traders Daily

Nov 04, 2024
pulisher
Nov 01, 2024

Third harmonic bio sees $14.3 million in stock sales by BVF Partners - Investing.com India

Nov 01, 2024
pulisher
Oct 31, 2024

Jade, another biotech spinout of Paragon, to merge with Aerovate - BioPharma Dive

Oct 31, 2024
pulisher
Oct 30, 2024

Third Harmonic Bio's chief medical officer sells $40,095 in stock - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

A new biotech, built around protein design, springs from David Baker’s lab - BioPharma Dive

Oct 30, 2024
pulisher
Oct 30, 2024

Harmonic Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Down -18.64% in 4 Weeks, Here's Why Philips (PHG) Looks Ripe for a Turnaround - MSN

Oct 29, 2024
pulisher
Oct 28, 2024

Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane - Seeking Alpha

Oct 28, 2024
pulisher
Oct 24, 2024

Where are the Opportunities in (THRD) - Stock Traders Daily

Oct 24, 2024
pulisher
Oct 24, 2024

Harmonic Discovery presents FLT3 kinase inhibitor with enhanced safety profile - BioWorld Online

Oct 24, 2024

Finanzdaten der Third Harmonic Bio Inc-Aktie (THRD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
Kapitalisierung:     |  Volumen (24h):